

EFFICACY DATA for Surface Disinfectant Cleaner

VIRUCIDAL DATA:

Test Method:

- U.S. E.P.A. Pesticide Assessment Guidelines, Subdivision G: Product Performance, Section 91-2 (f), and Section 91-30, (d), (e), November 1982.
- + Protocols for Testing the Efficacy of Disinfectants against Hepatitis B Virus (HBV) (EPA, Federal Register, Vol. 65, No. 166, 8/25/2000, p. 51828).
- Protocol for Testing Disinfectants against Hepatitis C Virus using Bovine Viral Diarrhea Virus as approved by the U.S. EPA on August 15, 2002.

Test Conditions: 0.5 oz/gal dilution, 10 minute contact time, 5% organic soil load, sterile glass petri dishes, 400 ppm hard water, 21-24°C exposure temperature

Results: Titer Reduction Sample **Test Organism** *Avian Influenza A Virus (H3N2) (Avian Reassortant) (ATCC VR-2072) AB >4.25 log10 >4.25 log10 *Avian Influenza Virus, Type A (Turkey/WIS/66) (H9N2) A B >4.0 log10 >4.0 log10 *Bovine rhinotracheitis, strain LA (ATCC VR-188) A B >5.0 log10 >5.0 log10 **‡Bovine Viral Diarrhea Virus (BVDV)** 5.9 log10 5.9 log10 A R A B >6.25 log10 >6.25 log10 *Canine distemper Virus, strain Lederle (ATCC VR-128) *Feline picornavirus, strain FRV (ATCC VR-649) АВ >4.25 log10 >4.25 log10 †Hepatitis B Virus (HBV) (Duck Hepatitis B Virus-DHBV) A B 4.5 log10 4.7 log10 **‡Hepatitis C Virus (HCV) (Bovine Viral Diarrhea Virus-BVDV)** A B 5.9 log10 5.9 log10 >5.0 log10 >5.0 log10 *Herpes Simplex Type 1 (ATCC VR-260) A B >6.0 log10 >6.0 log10 *Herpes Simplex Type 2 (ATCC VR-734) A B *Human Coronavirus (ATCC VR-740, strain 229E) AB >3.0 log10 >3.0 log10 *Human Immunodeficiency Virus, HTLV-IIIRF, strain of HIV-1 (associated with AIDS) A B >3.5 log10 >3.5 log10 *Human Immunodeficiency Virus Type 2 (HIV-2), strain CBL-20 A B >3.25 log10 >3.25 log10 *Influenza A2, strain Hong Kong (ATCC VR-544) AR >4.25 log10 >4.25 log10 *Pandemic 2009 H1N1 Influenza A Virus (Refer to Note on next page.) >3.0 log10 >3.0 log10 *Paramyxovirus (Mumps) (ATCC VR-1438) A B *Porcine Respiratory & Reproductive Syndrome Virus (PRRSV), strain NVSL A B >5.0 log10 >5.0 log10 *Pseudorabies, strain Aujeszky (ATCC VR-135) A B >5.25 log10 >5.25 log10 *Rabies Virus (attenuated CDC ERA strain) А В 3.0 log10 3.0 log10 *Rotavirus, strain SA-11 (ATCC VR-899) A B 4.5 log10 4.5 log10 A B 3.03 log10 3.03 log10 *SARS Associated Coronavirus (ZeptoMetrix) *Vaccinia, strain WR (ATCC VR-119) A B >5.5 log10 >5.5 log10

Conclusion: Under the conditions of this investigation, MARK3 Surface Disinfectant Cleaner demonstrated virucidal activity againstAvian Influenza A Virus (H3N2), Avian Influenza Virus, Type A (H9N2), Bovine rhinotracheitis, Bovine Viral Diarrhea Virus (BVDV), Canine distemper virus, Feline picornavirus, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Type 1, Herpes Simplex Type 2, Human Coronavirus, Human Immunodeficiency Virus (HIV-1), Human Immunodeficiency Virus Type 2 (HIV-2), Influenza A2, Pandemic 2009 H1N1 Influenza A Virus, Paramyxovirus (Mumps), Porcine Respiratory & Reproductive Syndrome Virus (PRRSV), Pseudorabies, Rabies Virus, Rotavirus, SARS Associated Coronavirus, and Vaccinia according to criteria established by the U.S. Environmental Protection Agency for registration and labeling of a disinfectant product as a virucide.

NOTE: Per the EPA guidance document dated October 21, 2009, disinfectant products that bear label claims against human, avian, or swine influenza A virus, and have submitted and received approval of efficacy data to support these label claims, may include a label claim against the Pandemic 2009 H1N1 Influenza A Virus.

Results:	Cample	No. of C	
Test Organism	Sample A	Exposed 10	0
Enterobacter cloaca	В	10	0
(ATCC 23355)	_		_
Enterobacter cloacae	Α	10	0
(clinical isolate)	В	10	0
,			
Enterococcus faecalis	Α	10	0
(ATCC 19433)	В	10	0
	٨	10	0
Enterococcus faecalis	A B	10	0
(clinical isolate)	U	10	Ū
Factoristic cali	Α	10	0
Escherichia coli (ATCC 11229)	В	10	0
(AICC 11225)	_		
Escherichia coli	Α	10	0
(clinical isolate)	В	10	0
Fusobacterium necrophorum	Α	10	0
(ATCC 27852)	В	10	0
	^	10	0
Gentamicin resistant Acinetobacter baumannii	A B	10	0
(Fairfax Hospital CI 02001)	J	10	•
Klebsiella pneumoniae subsp. Pneumoniae	Α	10	0
(ATCC 13883)	В	10	0
(ATCC 25555)			
Lactobacillus casei subsp. Rhamnosus	Α	10	0
(ATCC 7469)	В	10	0
		10	0
Levofloxacin resistant Acinetobacter baumannii	A B	10 10	0 0
(Fairfax Hospital CI 02001)	ь	10	U
Listada managidaganas	Α	10	0
Listeria monocytogenes (ATCC 35152)	В	10	0
(ATCC 35132)	_		
Methicillin Resistant Staphylococcus aureus (MRSA)	Α	10	0
(ATCC 33592)	В	10	0
Pasteurella multocida	Α	10	0
(ATCC 7707)	В	10	0
		10	0
Proteus mirabilis	A B	10	0
(ATCC 9921)	ь	10	Ū
Proteus mirabilis	Α	10	0
(ATCC 25933)	В	10	Ō
(AT CC ESSE)			
Proteus vulgaris	Α	10	0
(ATCC 13315)	В	10	0

Results:		No. of C	arriers
Test Organism	Sample	Exposed	Positive
Enterobacter cloaca	Α	10	0
(ATCC 23355)	В	10	0
Enterobacter cloacae	Α	10	0
(clinical isolate)	В	10	0
			973
Enterococcus faecalis	A	10	0
(ATCC 19433)	В	10	0
		40	•
Enterococcus faecalis	A	10	0
(clinical isolate)	В	10	0
		10	
Escherichia coli	A	10	0
(ATCC 11229)	В	10	0
		10	0
Escherichia coli	A B	10 10	0
(clinical isolate)	В	10	U
	Α	10	0
Fusobacterium necrophorum	В	10	0
(ATCC 27852)	ь	10	U
Gentamicin resistant Acinetobacter baumannii	Α	10	0
	В	10	0
(Fairfax Hospital CI 02001)	-	20	•
Klebsiella pneumoniae subsp. Pneumoniae	Α	10	0
(ATCC 13883)	В	10	0
(AICC 13863)			
Lactobacillus casei subsp. Rhamnosus	Α	10	0
(ATCC 7469)	В	10	0
(1100 / 105)			
Levofloxacin resistant Acinetobacter baumannii	Α	10	0
(Fairfax Hospital Ci 02001)	В	10	0
,			
Listeria monocytogenes	Α	10	0
(ATCC 35152)	В	10	0
Methicillin Resistant Staphylococcus aureus (MRSA)	Α	10	0
(ATCC 33592)	В	10	0
Pasteurella multocida	A	10	0
(ATCC 7707)	В	10	0
		10	0
Proteus mirabilis	A B	10 10	0
(ATCC 9921)	ь	10	U
A	Α	10	0
Proteus mirabilis	В	10	0
(ATCC 25933)	D	10	J
Dunta va valencie	Α	10	0
Proteus vulgaris	В	10	0
(ATCC 13315)		-5	•

Results:		No. of Ca	arriers
Test Organism	Sample	Exposed	
Pseudomonas fluorescens	Α	10	0
(ATCC 15916)	В	10	1
	С	10	0
Pseudomonas tolaasii	Α	10	0
(ATCC 33618)	В	10	0
Salmonella enterica subsp. enterica serotype paratyphi B	Α	10	0
(ATCC 8759)	В	10	Ö
Salmonella enterica subsp. enterica serotype pullorum	Α	10	0
(ATCC 9120)	В	10	0
Salmonella enterica subsp. enterica serotype typhi	Α	10	0
(ATCC 6539)	В	10	0
Salmonella enterica subsp. enterica serotype typhimurium	Α	10	0
(ATCC 14028)	В	10	0
Salmonella enterica subsp. enterica serotype enteritidis	Α	10	0
(ATCC 13076)	В	10	0
Serratia marcescens	А	10	0
(ATCC 8100)	В	10	0
Shigella dysenteriae	Α	10	0
(ATCC 12180)	В	10	0
Shigella flexneri Type 2bA1	Α	10	0
(ATCC 12022)	В	10	0
Shigella sonnei	Α	10	0
(ATCC 25931)	В	10	0
Staphylococcus aureus subsp. Aureus	Α	10	0
(ATCC 33592)	В	10	0
Staphylococcus aureus	Α	10	0
(clinical isolate)	В	10	0
Staphylococcus epidermidis	Α	10	0
(ATCC 29641)	В	10	0
Staphylococcus epidermidis	Α	10	0
(clinical isolate)	В	10	0
Streptococcus pyogenes Group A	Α	10	0
(ATCC 19615)	В	10	0
Streptococcus pyogenes	Α	10	0
(clinical-flesh eating strain, BIRD M3)	В	10	0

Results:		No. of C	arriers
Test Organism	Sample	Exposed	Positive
Tobramycin resistant Acinetobacter baumannii	Α	10	0
(Fairfax Hospital CI 02001)	В	10	0
Vancomycin Intermediate Resistant Staphylococcus aureus	Α	10	0
(VISA) (HIP-5836)	В	10	0
Vancomycin Resistant Enterococcus faecalis (VRE)	Α	10	0
(ATCC 51575)	В	10	0
Xanthamonas maltophilia	Α	10	0
(clinical isolate)	В	10	o
W. W			
Xanthomonas axonopodis (pathovar citri) when diluted at	Α	10	0
1.18 oz./gal. (1:108 dilution)	В	10	0

Conclusion: Under the conditions of these investigations, MARK3 Surface Disinfectant Cleaner demonstrated disinfectant activity against Staphylococcus aureus, Salmonella enterica, Pseudomonas aeruginosa PRD-10, Ampicillin resistant Acinetobacter baumannii, Bactrim resistant Acinetobacter baumannii, Bordetella bronchiseptica, Cefazolin resistant Acinetobacter baumannii, Ceftazdime resistant Acinetobacter baumannii, Ceftriaxone resistant Acinetobacter baumannii, Ciprofloxacin resistant Acinetobacter baumannii, Community Associated Methicillin Resistant Staphylococcus aureus (CAMRSA) (NRS 123, Genotype USA400), Community Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA) (NRS 384, Genotype USA300), Corynebacterium ammoniagenes, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Fusobacterium necrophorum, Gentamicin resistant Acinetobacter baumannii, Klebsiella pneumoniae subsp. pneumoniae, Lactobacillus casei subsp. rhamnosus, Levofloxacin resistant Acinetobacter baumannii, Listeria monocytogenes. Methicillin Resistant Staphylococcus aureus (MRSA), Pasteurella multocida, Proteus mirabilis (ATCC 9921), Proteus mirabilis (ATCC 25933), Proteus vulgaris, Pseudomonas fluorescens, Pseudomonas tolaasii, Salmonella enterica subsp. enterica serotype paratyphi B, Salmonella enterica subsp. enterica serotype pullorum, Salmonella enterica subsp. enterica serotype typhi, Salmonella enterica subsp. enterica serotype typhimurium, Salmonella enterica subsp. enterica serotype enteritidis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri Type 2b, Shigella sonnei, Staphylococcus aureus subsp. aureus, Staphylococcus epidermidis, Streptococcus pyogenes Group A, Streptococcus pyogenes (clinical-flesh eating strain, BIRD M3), Tobramycin resistant Acinetobacter baumannii, Vancomycin Intermediate Resistant Staphylococcus aureus (VISA) and Vancomycin Resistant Enterococcus faecalis (VRE), according to criteria established by the U.S. Environmental Protection Agency for registration and labeling of a disinfectant product as a bactericide.

MARK3 Surface Disinfectant Cleaner also demonstrated disinfectant activity against the following antibiotic resistant clinical isolates: Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Xanthamonas maltophilia.

When diluted at 1.18 oz./gal. (1:108 dilution), MARK3 Surface Disinfectant Cleaner demonstrated disinfectant activity against Xanthomonas axonopodis (pathovar citri) (Citrus Canker Disease).

BACTERICIDAL STABILITY DATA OF USE-SOLUTION:

Test Method: Use Dilution

Test Conditions: 5% organic soil load, 10 minute contact time, stainless steel carrier substrates,

400 ppm hard water, 20°C exposure temperature, 0.5 oz/gal dilution

Storage Conditions: sealed containers at room temperature

Results:

			No. of Carriers
Test Time	Sample	Test Organism	Exposed Positive
Zero Time	Α	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
	В	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
Week 1	Α	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
	В	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
Week 2	Α	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
	В	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
Week 3	Α	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
	В	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
Week 4	Α	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
	В	Staphylococcus aureus (ATCC 6538)	10 0
		Salmonella enterica (ATCC 10708)	10 0
		Pseudomonas aeruginosa (ATCC 15442)	10 0
		- · · · · · · · · · · · · · · · · · · ·	

Condusion:

The results of this investigation show that a 0.5 oz/gal use dilution of BTC® 885 Neutral Disinfectant Cleaner-256 will demonstrate disinfectant efficacy against *Staphylococcus aureus*, *Salmonella enterica*, and *Pseudomonas aeruginosa* for up to 4 weeks in accordance with criteria established by the U.S. Environmental Protection Agency for registration and labeling of a disinfectant product as a bactericide.